thejapantimes, to worldnews
@thejapantimes@mastodon.social avatar

Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use. https://www.japantimes.co.jp/news/2024/04/24/world/science-health/alzheimer-drug-us-adoption-slow/ #worldnews #sciencehealth #alzheimers #brain #eisai #biogen #leqembi #us

itnewsbot, to science

Biogen dumps dubious Alzheimer’s drug after profit-killing FDA scandal - Enlarge / The exterior of the headquarters of biotechnology company Bio... - https://arstechnica.com/?p=2000435

thejapantimes, to Japan
@thejapantimes@mastodon.social avatar

New Alzheimer's drug lecanemab will cost around ¥2.98 million per year in Japan, but will be largely covered by public health insurance that will limit the burden for patients to between 10% and 30% of that cost, subject to a cap, a health ministry body has said. https://www.japantimes.co.jp/news/2023/12/13/japan/eisai-biogen-alzheimers-drug-price/?utm_content=buffer4dd52&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #japan #alzheimer039s #drugs #eisai #biogen #pharmaceuticals

  • All
  • Subscribed
  • Moderated
  • Favorites
  • provamag3
  • thenastyranch
  • magazineikmin
  • tacticalgear
  • cisconetworking
  • ethstaker
  • rosin
  • love
  • Youngstown
  • slotface
  • khanakhh
  • kavyap
  • osvaldo12
  • DreamBathrooms
  • megavids
  • everett
  • InstantRegret
  • tester
  • normalnudes
  • ngwrru68w68
  • cubers
  • GTA5RPClips
  • mdbf
  • Durango
  • anitta
  • modclub
  • Leos
  • JUstTest
  • All magazines